XML 94 R83.htm IDEA: XBRL DOCUMENT v3.26.1
Segment Reporting - Summary of Significant Segment Expenses (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
REVENUES:            
Total revenues $ 496,009   $ 390,657   $ 888,920 $ 697,167
EXPENSES:            
Cost of goods manufactured and sold (exclusive of amortization of acquired intangible assets shown below) 98,112   49,460   159,690 98,657
Development programs:            
Alixorexton 28,797   23,795   54,294 41,649
LYBALVI 4,939   5,050   9,388 8,901
LUMRYZ 4,710   0   7,633 0
Other orexin programs 15,090   2,709   21,944 6,178
Other external R&D expenses 13,832   7,880   24,938 15,384
Total external R&D expenses 67,368   39,434   118,197 72,112
Internal R&D expenses:            
Employee-related 37,013   30,651   80,627 62,005
Occupancy 3,335   3,308   6,599 6,455
Depreciation 1,850   1,474   3,537 2,942
Other internal R&D expenses 3,354   2,503   7,305 5,673
Total internal R&D expenses 45,552   37,936   98,068 77,075
R&D expenses 112,920   77,370   216,265 149,187
Selling, general and administrative expenses:            
Selling and marketing expense 154,364   121,175   309,276 244,109
General and administrative expense 63,261   49,674   172,942 98,444
Total selling, general and administrative expense 217,625   170,849   482,218 342,553
Other segment (expense) income [1] (66,851)   (5,880)   (96,726) 2,792
NET (LOSS) INCOME $ 501 $ (66,480) $ 87,098 $ 22,464 $ (65,979) $ 109,562
[1] “Other segment (expense) income” during the three and six months ended June 30, 2026 and 2025, includes “Amortization of acquired intangible assets”, “Change in fair value of contingent consideration”, “Total other (expense) income, net” and “Income tax provision (benefit)”.